|
Feb 19
|
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 19
|
Exact Sciences: Q4 Earnings Snapshot
|
|
Feb 19
|
Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue
|
|
Feb 19
|
Exact Sciences Announces Fourth Quarter 2024 Results
|
|
Feb 18
|
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
|
|
Feb 13
|
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Feb 12
|
Trickle-down effect of NIH funding battle worries healthcare analysts and medical experts
|
|
Feb 12
|
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Feb 10
|
When Can We Expect A Profit From Exact Sciences Corporation (NASDAQ:EXAS)?
|
|
Jan 3
|
Exact Sciences price target raised to $70 from $60 at Evercore ISI
|
|
Jan 2
|
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
|
|
Oct 9
|
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Oct 8
|
Exact Sciences Schedules Third Quarter 2024 Earnings Call
|
|
Oct 7
|
FDA greenlights Exact Science’s newest home colorectal cancer test
|
|
Oct 7
|
High Growth Tech Stocks in the United States for October 2024
|
|
Oct 7
|
Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test
|
|
Oct 5
|
Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio
|
|
Oct 4
|
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
|
|
Oct 4
|
Exact Sciences Stock Rises After FDA Signs Off On New Cologuard
|
|
Oct 4
|
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
|